Research output

  1. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

    Research output: Contribution to journal › Article › Academic › peer-review

  2. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

    Research output: Contribution to journal › Article › Academic › peer-review

View all (2) »

ID: 46924